Keyword: Sunovion Pharmaceuticals
AbbVie's Humira held on to its ad spending crown yet again in May, but Sunovion's Latuda jumped up to knock Pfizer's Lyrica out of second place.
Sunovion is looking for a hero. Epilepsy heroes, that is.
AbbVie’s Humira finished the last month of 2016 in much the same way it did most of the year—as the No. 1 national TV ad spender among pharma brands.
Sunovion’s COPD treatment passed muster in Phase III for both safety and efficacy, marking a success for its quick-acting nebulizer delivery system.